Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I, Open Label, Non-Randomised Study to Assess the Effect of Rifampicin on the Pharmacokinetics of Multiple Oral Doses of Cediranib (AZD2171, RECENTIN™), in Patients With Advanced Solid Tumours

NCT00750841 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT00750841
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00750841 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I, Open Label, Non-Randomised Study to Assess the Effect of Rifampicin on the Pharmacokinetics of Multiple Oral Doses of Cediranib (AZD2171, RECENTIN™), in Patients With Advanced Solid Tumours
Lead sponsor
AstraZeneca
Phase
Phase 1
Overall status
Active, not recruiting
Start date
September 9, 2008
Completion date
December 31, 2026
Enrollment
64 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

solid tumors